Tianeptine, a substance colloquially known as "gas station heroin," is rapidly spreading across the United States, raising alarms among federal health officials, emergency room physicians, and state lawmakers. This tricyclic antidepressant, never approved for any medical use by the U.S. Food and Drug Administration (FDA), has prompted an accelerating response from authorities concerned about its potent, opioid-like effects and high potential for addiction.
The FDA has officially acknowledged tianeptine's potency, noting that at elevated doses, it surpasses morphine and rivals some of the most addictive opioids known to medicine. Countries where tianeptine holds legal prescription status have already revised their warning labels, explicitly cautioning patients about its addictive properties. The Drug Enforcement Administration (DEA) defines the practical dangers of its misuse, which include respiratory failure, extreme sedation, and, in the most severe instances, death.
Sellers frequently market tianeptine as a wellness product, claiming it alleviates pain, anxiety, and depression, or enhances mental sharpness. It is available in various forms, including pills, powders, salts, and liquids, often sold under brand names such as Tianaa, ZaZa, Neptune’s Fix, Pegasus, and TD Red, primarily in convenience stores and gas stations. This marketing strategy often bypasses regulatory scrutiny by presenting the substance as a dietary supplement, despite the FDA never clearing it for such use.
In response to the growing public health threat, fourteen states have already taken decisive action, formally classifying tianeptine under Schedule I, the most restrictive category in controlled substance law. Connecticut recently joined this list, becoming the latest state to impose a complete ban on tianeptine sales and use. Connecticut's Lieutenant Governor, Susan Bysiewicz, highlighted the deceptive marketing tactics used to promote these substances. "With false marketing that led consumers to believe these are safe products, and with candy-like flavor options, these substances posed a clear threat to those battling substance-use disorder and our youngest residents," Bysiewicz stated, as reported by Fox News.
The crackdown in Connecticut extended beyond tianeptine, with several other substances—including Kratom, 7-hydroxymitragynine, Bromazolam, Flubromazolam, Nitazenes, and Phenibut—also being added to the state’s controlled substance list in the same legislative action.
FDA Commissioner Martin Makary took the unusual step of issuing a direct public warning earlier this month, emphasizing the severe risks associated with tianeptine. "I am very concerned," Makary wrote, according to Fox, adding, "I want the public to be especially aware of this dangerous product and the serious and continuing risk it poses to America’s youth."
Dr. Robert Schwaner, vice chair of system clinical affairs at Stony Brook Emergency Medicine in New York, further elaborated on the drug's dangerous mechanism. He confirmed that the FDA has never approved tianeptine for dietary supplement use, a classification some sellers exploit to legally stock the product. Dr. Schwaner explained the physiological effects, stating, "The euphoria at low doses is primarily due to increased serotonergic activity from its serotonin reuptake effects. With increasing doses, the mu-opioid receptor stimulation may become lethal." He detailed the progression that can lead to fatalities: "As with heroin and other opioids, significant mu-opioid receptor stimulation ultimately results in a loss of respiratory drive and subsequent cardiac arrest."
Dr. Schwaner argued that a state-by-state approach is insufficient to combat the pervasive threat of tianeptine. "Acting at the same receptor as opioids, tianeptine has the potential for an individual to develop tolerance, subsequent dependence and withdrawal from its use," he warned, advocating for a comprehensive federal solution to address the substance's widespread availability and addictive nature. In response to these concerns, bipartisan federal legislation, known as the STAND Against Emerging Opioids Act, has been introduced in Congress. This act proposes to place tianeptine and its chemical relatives under Schedule III of the federal Controlled Substances Act, which would necessitate a prescription for any legal access to the substance. This legislative effort underscores a growing recognition of the need for a unified national strategy to address the emerging dangers of "gas station heroin."
